New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma image credit: Bamboo Works Key Takeaways: New
A cancer medicine called Iza-bren got approved in China to treat more types of cancer. This shows China is becoming a bigger player in making advanced medicines, which could mean more customers and growth chances for companies like Bristol Myers that work there.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.